Go to JCI Insight
Jci spelled out white on transparent.20160208
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • Fibrosis (Jan 2018)
    • Glia and Neurodegeneration (Sep 2017)
    • Transplantation (Jun 2017)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

Jci only white

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis
Sassan HajMohammadi, … , Robert D. Rosenberg, Nicholas W. Shworak
Sassan HajMohammadi, … , Robert D. Rosenberg, Nicholas W. Shworak
Published April 1, 2003
Citation Information: J Clin Invest. 2003;111(7):989-999. https://doi.org/10.1172/JCI15809.
View: Text | PDF
Categories: Article Hematology

Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis

  • Text
  • PDF
Abstract

Endothelial cell production of anticoagulant heparan sulfate (HSact) is controlled by the Hs3st1 gene, which encodes the rate-limiting enzyme heparan sulfate 3-O-sulfotransferase-1 (3-OST-1). In vitro, HSact dramatically enhances the neutralization of coagulation proteases by antithrombin. The in vivo role of HSact was evaluated by generating Hs3st1–/– knockout mice. Hs3st1–/– animals were devoid of 3-OST-1 enzyme activity in plasma and tissue extracts. Nulls showed dramatic reductions in tissue levels of HSact but maintained wild-type levels of tissue fibrin accumulation under both normoxic and hypoxic conditions. Given that vascular HSact predominantly occurs in the subendothelial matrix, mice were subjected to a carotid artery injury assay in which ferric chloride administration induces de-endothelialization and occlusive thrombosis. Hs3st1–/– and Hs3st1+/+ mice yielded indistinguishable occlusion times and comparable levels of thrombin•antithrombin complexes. Thus, Hs3st1–/– mice did not show an obvious procoagulant phenotype. Instead, Hs3st1–/– mice exhibited genetic background–specific lethality and intrauterine growth retardation, without evidence of a gross coagulopathy. Our results demonstrate that the 3-OST-1 enzyme produces the majority of tissue HSact. Surprisingly, this bulk of HSact is not essential for normal hemostasis in mice. Instead, 3-OST-1–deficient mice exhibited unanticipated phenotypes suggesting that HSact or additional 3-OST-1–derived structures may serve alternate biologic roles.

Authors

Sassan HajMohammadi, Keiichi Enjyoji, Marc Princivalle, Patricia Christi, Miroslav Lech, David Beeler, Helen Rayburn, John J. Schwartz, Samad Barzegar, Ariane I. de Agostini, Mark J. Post, Robert D. Rosenberg, Nicholas W. Shworak

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Disruption of the mouse Hs3st1 locus. (a) Gene-targeting strategy. Exon ...
Disruption of the mouse Hs3st1 locus. (a) Gene-targeting strategy. Exon 8 bridges two BamHI fragments and includes the entire coding sequence (white box) flanked by 5′ and 3′ noncoding sequences (dark gray boxes). The targeting construct replaces exon 8 with a neor expression cassette (light gray boxes) in the same transcriptional orientation. The disrupted locus lacks specific BamHI, SpeI, and BglI sites. Restriction sites for producing targeting arms are shown. Also indicated are the locations of 5′ and 3′ probes for Southern blot analysis genotyping and primer sites for PCR analysis genotyping. (b) Genotyping by Southern blotting. Mouse tail genomic DNA was digested with BamHI, then the Hs3st1 locus was detected with the external 5′ probe (shown in a). The wild-type allele generates a 5.6-kb band, whereas the disrupted allele generates a 12.7-kb band due to loss of a BamHI site. (c) 3-OST-1 activity of mouse plasma and tissue homogenates; n = 3 littermates per group. 3-OST-1 activity creates AT-binding sites within HS (producing HSact) and is determined by incubating tissue homogenate or plasma samples with [35S]HS and PAPS, then measuring the resultant [35S]HSact by AT-affinity chromatography.
Follow JCI: Facebook logo white Twitter logo v2 Rss icon
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts